Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
about
Systemic VHL gene functions and the VHL diseaseClinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasisCbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction.VHL, the story of a tumour suppressor gene.The multifaceted von Hippel-Lindau tumour suppressor protein.Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modificationsSOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor.Emerging EPO and EPO receptor regulators and signal transducers.Renal cancer: oxygen meets metabolismSOCS, Inflammation, and Autoimmunity.The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W).ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemiaCongenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range.Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.Roles of the hypoxia response system in hematopoietic and leukemic stem cells.Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.Congenital erythrocytosis.Investigation and Management of Erythrocytosis.Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.Diagnosis and management of congenital and idiopathic erythrocytosis.Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.Cardiopulmonary phenotype associated with human PHD2 mutation.Genetic basis of congenital erythrocytosis: mutation update and online databases.Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.Complications in children and adolescents with Chuvash polycythemia.CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.The HIF and other quandaries in VHL disease.Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia.BC-Box Motif-Mediated Neuronal Differentiation of Somatic Stem Cells.JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase
P2860
Q24605882-80C54177-1624-4E92-B274-935386A28A7FQ27853398-E32E437D-488D-49C3-9B3B-20F010A9829FQ28511495-F2105620-F8AA-4367-8D3D-1C531B0AB833Q33870784-DA550CAC-FC95-431C-828E-23B47950C7F1Q34455226-F2044A6F-2BCA-4F51-A5FA-135F2F87DCB7Q34660062-CBD9DEB0-5F0B-46C8-B172-6D4750CF011FQ34987659-AED567BD-A28F-400F-8359-1DE73A8D0B4BQ35006328-63FBE7A0-B6C1-4173-BA17-62C0D5CFFDBBQ35692391-D0F5F659-C201-4903-BBA9-CC38E77424E5Q35907065-32D41CD8-28E5-43F2-A199-87AA9E92F63AQ35927538-917F6F62-7FB1-48AD-9458-9B903086DD5BQ36862486-A777FFE1-4E55-4D39-845D-DA37942F4E7EQ36879241-9194C2DD-808C-4406-9D3F-09FED05E8D80Q37138199-7EFF7105-259F-4FCF-B225-72FD620EC8D4Q37212727-E929071B-D705-4585-BF25-8A0FC731D112Q37685596-D2CF1222-4F3C-40D9-8833-82EE10F10D5DQ38005966-AE39707B-9F58-487F-AE1F-863E69D2BC8DQ38595266-F24BE257-CED4-40A0-B868-118F450C0006Q38830441-839BC97F-A462-4756-B8DF-FA51B6A9A92DQ38898732-AE90FB8D-68C9-4B81-AA79-4C96A7A43D11Q39770199-36EEB2C4-83BF-42E5-B091-6709DE86F9C4Q39869449-DD3D0FA1-62FA-4F6F-A64A-67D315D264D5Q41384272-3BC4CB69-76FA-47AF-BB1F-AD1466954190Q42291369-F87ACBC3-562C-4B7F-BA90-0390166977A3Q42622691-3907F10F-43C1-476A-9A5D-C68953B7CC25Q42725814-992F746D-DE99-4393-AE42-DD5542BCE9D6Q43096801-4C6626D2-3409-4BF1-85D9-3DD990628D56Q43293633-BD675153-2CA3-4770-B0D7-098A3A2A1109Q45363184-DCEEA1BA-3B86-4D2A-AEE3-D56F166782D5Q50026055-287DF834-5D18-4790-AF04-8526A1114AE7Q52685425-532C2CDC-70D6-4F14-A26A-2254C95EDD40Q52699503-0C4F3985-E998-426B-B60D-33BF587EEB26Q54513818-37D07021-1BC7-48F6-8095-E287C94D04E1Q57167826-5839E772-319E-422B-B01A-55A7D13A7793
P2860
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Loss of JAK2 regulation via a ...... nderlies Chuvash polycythemia.
@en
Loss of JAK2 regulation via a ...... nderlies Chuvash polycythemia.
@nl
type
label
Loss of JAK2 regulation via a ...... nderlies Chuvash polycythemia.
@en
Loss of JAK2 regulation via a ...... nderlies Chuvash polycythemia.
@nl
prefLabel
Loss of JAK2 regulation via a ...... nderlies Chuvash polycythemia.
@en
Loss of JAK2 regulation via a ...... nderlies Chuvash polycythemia.
@nl
P2093
P2860
P356
P1433
P1476
Loss of JAK2 regulation via a ...... underlies Chuvash polycythemia
@en
P2093
David A Cheresh
Dwayne L Barber
Lukasz M Boba
M Celeste Simon
Meredith S Irwin
Michael Ohh
Michele M Hickey
Pardeep Heir
Roxana I Sufan
P2860
P2888
P304
P356
10.1038/NM.2370
P407
P577
2011-06-19T00:00:00Z